◀ Back to IFNA21

IFNA21 — TGFB1

Text-mined interactions from Literome

Guido et al., Mod Pathol 2006 (Fibrosis...) : The aim of this study was to evaluate the effects of interferon alpha and ribavirin in combination therapy on the tissue expression of nuclear-factor kB ( NF-kappaB) (a transcription factor coordinating the expression of stress genes involved in immune response and inflammation ), of the polypeptide transforming growth factor beta-1 ( TGF-beta1 ) and matrix metalloproteinases 1 (MMP-1) ( both of which play an important part in the pathological process of liver fibrogenesis ), and on the serum levels of soluble TGF-beta1 , tissue inhibitors of metalloproteinases ( TIMP ) -1, and active endogenous MMP-2 and MMP-9 in paired ( pre- and post-treatment ) liver biopsy and serum samples of subjects with chronic hepatitis C. Serum levels of TGF-beta1, TIMP-1, MMP-2, and MMP-9 were evaluated by enzyme linked immunosorbent assay
Bekeredjian-Ding et al., Immunology 2009 (Head and Neck Neoplasms) : Here we demonstrate that tumour derived prostaglandin E2 ( PGE ( 2 ) ) and transforming growth factor-beta ( TGF-beta ) increase interleukin-8 (IL-8) but synergistically inhibit interferon-alpha ( IFN-alpha ) and tumour necrosis factor (TNF) production of Toll-like receptor 7 (TLR7)- and Toll-like receptor 9 (TLR9) stimulated PDC
Jahn et al., Cancer Immunol Immunother 1994 (Carcinoma, Renal Cell...) : In vivo regulation of transforming growth factor beta 1 transcription by immunotherapy : interleukin-2 impairs interferon-alpha stimulated increase in steady-state mRNA levels of transforming growth factor beta 1